Sugi Predict

Sugi Predict / Compounds / SCHEMBL4063597

SCHEMBL4063597

SCHEMBL4063597

CCOC(=O)C(Cc1ccccc1[N+](=O)[O-])(NC(C)=O)C(=O)OCC

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.62
▸ RECQL P46063 1/20 0.62
▸ MAPK1 P28482 2/20 0.49
▸ PKM P14618 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ ATM Q13315 2/20 0.47
▸ THRB P10828 1/20 0.47
▸ HTT P42858 1/20 0.46
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ MAOB P27338 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7422196 0.96 ALDH1A1 (0.58) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL10500092 0.89 ALDH1A1 (0.54) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL9432335 0.84 ALDH1A1 (0.55) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL3768538 0.83 ALDH1A1 (0.51) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL22204298 0.83 ALDH1A1 (0.51) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL25331477 0.83 ALDH1A1 (0.51) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL3771863 0.83 ALDH1A1 (0.51) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL4897313 0.83 ALDH1A1 (0.56) ALDH1A1RECQLMAPK1PKMKDM4E
SCHEMBL7425417 0.83 CYP2C19 (0.47) ALDH1A1KDM4ETHRBMEN1KMT2A
SCHEMBL3808666 0.81 ALDH1A1 (0.54) ALDH1A1RECQLMAPK1PKMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378202-B2 Tetrahydrobenzoazepinones and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2025-08-05 — — US disclosed
US-20240262792-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. 2024-08-08 — — US disclosed
US-20240025856-A1 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER CISTIM LEUVEN VZW (BE) 2024-01-25 — — US disclosed
US-20240025856-A1 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER CISTIM LEUVEN VZW (BE) 2024-01-25 — — US disclosed
US-11845724-B2 USP30 inhibitors and uses thereof VINCERE BIOSCIENCES, INC. (US) 2023-12-19 — — US disclosed
CN-116783165-A 1,2,3, 4-tetrahydroquinoline derivatives as YAP/TAZ-TEAD activation inhibitors for the treatment of cancer 天主教鲁汶大学 2023-09-19 — — CN disclosed
US-20230278962-A1 Tetrahydrobenzoazepinones and Related Analogs for Inhibiting YAP/TAZ-TEAD KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-09-07 — — US disclosed
EP-4222143-A1 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER Katholieke Universiteit Leuven (BE) 2023-08-09 — — EP disclosed
WO-2023122781-A2 TETRAHYDROBENZOAZEPINONES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-06-29 — — WO disclosed
US-20220315531-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. 2022-10-06 — — US disclosed
EP-0680469-B1 AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME BOEHRINGER INGELHEIM PHARMA (DE) 2000-04-26 — — EP disclosed
EP-0968198-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING $g(b)-AMYLOID PEPTIDE Elan Pharmaceuticals, Inc. (US) 2000-01-05 — — EP disclosed
WO-1999067221-A1 COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS ELAN PHARMACEUTICALS, INC. (US) 1999-12-29 — — WO disclosed
EP-0951466-A2 CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS Elan Pharmaceuticals, Inc. (US) 1999-10-27 — — EP disclosed
WO-1998038177-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING β-AMYLOID PEPTIDE ELAN PHARMACEUTICALS, INC. (US) 1998-09-03 — — WO disclosed
WO-1998028268-A2 CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 1998-07-02 — — WO disclosed
US-5616620-A HYPOTENSIVE AGENTS KARL THOMAE GMBH (DE) 1997-04-01 — — US disclosed
EP-0680469-A1 AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME Dr. Karl Thomae GmbH (DE) 1995-11-08 — — EP disclosed
WO-1994017035-A1 AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME DR. KARL THOMAE GMBH (DE) 1994-08-04 — — WO disclosed
US-4668686-A 1,3-DIHYDRO-2H-IMIDAZO/4,5-B/QUINOLINE-2-ONES BRISTOL-MYERS COMPANY (US) 1987-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025856-A1 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER YAP1, TEAD2, TEAD1 ALDH1A1 1569/4885RECQL 1529/4885MAPK1 1086/4885
US-20230278962-A1 Tetrahydrobenzoazepinones and Related Analogs for Inhibiting YAP/TAZ-TEAD YAP1, TEAD2, TEAD4 ALDH1A1 2369/4885RECQL 3790/4885MAPK1 2423/4885
US-12378202-B2 Tetrahydrobenzoazepinones and related analogs for inhibiting YAP/TAZ-TEAD YAP1, TEAD2, TEAD4 ALDH1A1 2369/4885RECQL 3790/4885MAPK1 2423/4885
US-11845724-B2 USP30 inhibitors and uses thereof USP30, USP28, USP1 ALDH1A1 2021/4885RECQL 1217/4885MAPK1 2205/4885
US-20220315531-A1 USP30 INHIBITORS AND USES THEREOF USP30, USP28, USP1 ALDH1A1 2021/4885RECQL 1217/4885MAPK1 2205/4885
US-20240262792-A1 USP30 INHIBITORS AND USES THEREOF USP30, USP28, USP1 ALDH1A1 2021/4885RECQL 1217/4885MAPK1 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.